Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound
paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective
when combined to treat advanced pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
HonorHealth Research Institute
Collaborators:
Bristol-Myers Squibb Lustgarten Foundation Translational Genomics Research Institute